Clinical Trials Logo

Premenopause clinical trials

View clinical trials related to Premenopause.

Filter by:
  • None
  • Page 1

NCT ID: NCT06206057 Not yet recruiting - Anxiety Clinical Trials

The Relationship Between Leisure Activities and Aging Anxiety in Women

Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about the effect of leisure activities on aging anxiety of middle-aged (45-59) women. The main question it aims to answer is: Do the leisure activities (doing sports, playing music instruments, doing handicrafts, writing, taking care of a pet, growing plants, dancing etc.) affect the aging anxiety level of middle-aged women? Participants will be required to fill out a form querying their socio-demographic information, medical histories, and regular leisure activities. Subsequently, the "Aging Anxiety Scale for Middle-Aged Women" will be applied.

NCT ID: NCT05795504 Enrolling by invitation - Clinical trials for Vitamin D Deficiency

Resistive Exercise Versus HIIT on Calcium and Vitamin D

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

A comparison between resistive exercise and high intensity interval trainig on calcium and vitamin d in premenopausal women.

NCT ID: NCT05299983 Active, not recruiting - Menopause Clinical Trials

MyMenoPlan: Online Resource for Improving Women's Menopause Knowledge and Informed Decision-making

Start date: January 15, 2022
Phase: N/A
Study type: Interventional

As part of a National Institute on Aging -funded R01, the investigators developed an evidence-based, multi-media digital resource entitled MyMenoPlan to help women learn about the menopause transition, and the symptoms and treatments of perimenopause/menopause. MyMenoPlan is also designed to help women learn about the effectiveness of treatments for a comprehensive list of midlife symptoms and compare treatments that may help with the specific symptoms women are experiencing.

NCT ID: NCT04778072 Active, not recruiting - Clinical trials for Iron Deficiency Anemia

A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects

Start date: October 8, 2018
Phase: N/A
Study type: Interventional

A randomized, placebo controlled, parallel group, double blind study to compare the 3-month adherence and efficacy of Active Iron in subjects with or at-risk of iron deficiency and a history of intolerance to oral iron. Subjects with intolerance and treatment failure due to oral iron (male and female subjects, aged 18 to 55 years, with mild to moderate iron deficiency, with or without anaemia) are eligible. Sixty subjects are randomised into three groups (14 mg elemental iron, 25mg elemental iron and 50mg elemental iron daily). The primary objective is to assess adherence/persistence (including using pill counts). Secondary objectives are to assess gastrointestinal tolerability, haematological efficacy and health related quality of life.

NCT ID: NCT03331536 Completed - Osteoporosis Clinical Trials

Skeletal Health in Bariatric Surgery Patients

Start date: March 22, 2018
Phase:
Study type: Observational

The investigators propose a prospective cohort trial that will help to understand the impact of Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG) in pre- and post-menopausal female bariatric patients.

NCT ID: NCT00901589 Completed - Postmenopause Clinical Trials

Marine n-3 Polyunsaturated Fatty Acids in Pre- and Postmenopausal Women

Start date: August 2007
Phase: N/A
Study type: Interventional

The study is a randomised placebo controlled double-blinded clinical trial where a group of healthy pre- and postmenopausal women is randomised to the intake of fish oil capsules or placebo oil capsules for 12 weeks. Anthropometric measurements(weight, height,blood pressure) blood samples and adipose tissue biopsies will be taken in order to illustrate the effect of marine n-3 PUFAs (fish oil) on the concentration of circulating female hormones and to investigate what impact menopause might have on the ability to incorporate marine n-3 PUFAs into tissues.

NCT ID: NCT00628121 Completed - Premenopause Clinical Trials

Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer

Start date: April 2006
Phase: N/A
Study type: Interventional

GnRH analogs are globally used for assisted reproduction in infertile patients. To date, in healthy female volunteers the pharmacokinetic and pharmacodynamic profiles of cetrorelix when administered in a single dose have been investigated in studies conducted using doses of 1, 3 and 5 mg. Studies performed in premenopausal female volunteers confirmed that cetrorelix rapidly suppresses luteinizing hormone (LH) and estradiol and shows dose-dependent prolongation of the duration of LH suppression. However, there have been few reports of studies of the relationship between the cetrorelix dosage and its effect on LH surge. In the present study, we investigated the effect of cetrorelix on LH surge when this drug was administered in single doses of 1, 2 and 3 mg.

NCT ID: NCT00455962 Active, not recruiting - Healthy Clinical Trials

Effect of Race on Gonadotropin Responses

Start date: January 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to attempt to determine why estrogen levels are increased in African-American women as compared to Caucasian women by evaluating estrogen feedback on the brain. African-American women have increased bone mineral density, higher rates of twins, greater incidence of fibroids, and increased incidence of breast cancer below 40 years of age as compared to Caucasian women. These traits or illnesses are all believed to be estrogen-dependent. In fact, previous research has demonstrated increased estrogen levels in African-American women as compared to Caucasian women. However, the reason for these differences in estrogen levels has not been studied in humans. One possibility is that estrogen feedback on the brain differs between African-American and Caucasian women. Two small glands in the brain (hypothalamus and pituitary) respond to estrogen. The hypothalamus secretes GnRH (Gonadotropin-Releasing Hormone) that signals the pituitary to secrete the reproductive hormones, LH (Luteinizing Hormone) and FSH (Follicle Stimulating Hormone). These hormones act on the ovaries and signal the ovaries to produce estrogen and progesterone. Estrogen in the bloodstream then acts on the brain to stop this system when the blood has enough estrogen levels. This is called estrogen feedback. This study will determine whether there are differences in estrogen feedback between African-American and Caucasian women.

NCT ID: NCT00361075 Completed - Clinical trials for Cardiovascular Disease

Midlife Cholesterol Study

Start date: July 1998
Phase: Phase 4
Study type: Interventional

The postmenopausal state is associated with an increase risk for heart disease. Much of this increase in risk may be due to the loss of estrogen (the main female hormone) and the effect of this loss on lipids (blood fats). This loss of estrogen is often treated by estrogen replacement therapy. Estrogen replacement therapy seems to have a beneficial effect on lipid levels. The purpose of this research study is to understand 1) how menopause affects lipids and 2) how hormone replacement therapy effects the lipid metabolism of postmenopausal women.